Posts by: Jose Marques Lopes, PhD

News, PAH News

Age, ischemic heart disease, and kidney dysfunction are important predictors of outcomes in patients with idiopathic pulmonary arterial hypertension (IPAH), a Swedish study shows. The research, “Impact of age and ... Read more

May 2, 2018May 2, 2018

Activation of PPAR-gamma May Be Potential Strategy Against PAH, Other Disorders, Study Suggests

News

Activation of a molecule called PPAR-gamma may be a future strategy to prevent pulmonary arterial hypertension (PAH) and other cardiovascular/pulmonary diseases, a study suggests. Findings were reported in the study, ... Read more

April 26, 2018April 26, 2018

Right Ventricular Function Determines Survival in PAH Patients, Study Reports

News, PAH News

Right ventricular function of the heart is the primary determining factor of survival in patients with pulmonary arterial hypertension (PAH) receiving specific treatments, a study suggests. The study, “Predictors ... Read more

April 13, 2018April 13, 2018

Ralinepag Reduces PAH Patients’ Risk of Death, Phase 2 Trial Shows

News, PAH News

Arena Pharmaceuticals’ ralinepag reduced the risk of pulmonary arterial hypertension patients dying, a Phase 2 clinical trial showed. Temple University Professor Raymond Benza will present the results at the International Society for ... Read more

April 11, 2018April 11, 2018

Young PH Patients Have Increased Risk During Cardiac Catheterization, Study Contends

News

Children with pulmonary hypertension (PH) are a relatively high-risk group for cardiac catheterization, a new study shows. In turn, hospital experience with the procedure reduces this risk. The research ... Read more

March 23, 2018April 1, 2018

Bardoxolone Methyl Improves Exercise Capacity of PH Patients with ILD in Phase 2 Trial

News, PAH News

Bardoxolone methyl, Reata Pharmaceuticals’ treatment candidate for pulmonary hypertension (PH), improves exercise capacity and has a safe profile in patients with PH associated with interstitial lung disease (ILD), according to ... Read more

March 15, 2018March 15, 2018

Reviva’s Pulmonary Hypertension Therapy Works Even Better in Combos, Study Shows

News, PAH News

Combinations of Reviva Pharmaceuticals’ RP5063 and other pulmonary arterial hypertension treatments improved rats’ lung blood vessel structure and lung function, a study reports. Previous research in rats indicated that RP5063 could ... Read more

February 23, 2018February 23, 2018

Remodulin Safe, Effective in Treating CTD-PAH for 12 Months, Observational Study Shows

News, PAH News

Subcutaneous Remodulin (treprostinil), marketed by United Therapeutics, is to be safe and effective for at least 12 months in patients with congenital heart disease-related pulmonary arterial hypertension (CTD-PAH), an observational study ... Read more

February 16, 2018February 16, 2018

Review Study Supports Tracleer as Effective Treatment in Pulmonary Arterial Hypertension

CTEPH News, News, PAH News

Treatment with Tracleer (bosentan) is effective in patients with pulmonary arterial hypertension (PAH), a new review study and analysis of data from clinical trials shows. The research, “Bosentan Therapy ... Read more

February 5, 2018February 5, 2018

AIT Acquires Nitric Oxide Delivery System to Treat Newborns with PH

News, PH News

AIT Therapeutics has acquired a global, exclusive license from NitricGen for a new nitric oxide (NO) delivery system that may benefit newborns with pulmonary hypertension (PH). Under terms of the deal for the ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Age, Certain Comorbidities Predict Outcomes in Idiopathic PAH Patients, Study Shows

Activation of PPAR-gamma May Be Potential Strategy Against PAH, Other Disorders, Study Suggests

Right Ventricular Function Determines Survival in PAH Patients, Study Reports

Ralinepag Reduces PAH Patients’ Risk of Death, Phase 2 Trial Shows

Young PH Patients Have Increased Risk During Cardiac Catheterization, Study Contends

Bardoxolone Methyl Improves Exercise Capacity of PH Patients with ILD in Phase 2 Trial

Reviva’s Pulmonary Hypertension Therapy Works Even Better in Combos, Study Shows

Remodulin Safe, Effective in Treating CTD-PAH for 12 Months, Observational Study Shows

Review Study Supports Tracleer as Effective Treatment in Pulmonary Arterial Hypertension

AIT Acquires Nitric Oxide Delivery System to Treat Newborns with PH

Pin It on Pinterest